Success Metrics

Clinical Success Rate
85.4%

Based on 35 completed trials

Completion Rate
85%(35/41)
Active Trials
4(7%)
Results Posted
40%(14 trials)
Terminated
6(10%)

Phase Distribution

Ph phase_2
9
15%
Ph early_phase_1
1
2%
Ph phase_3
8
13%
Ph phase_4
8
13%
Ph phase_1
7
12%
Ph not_applicable
24
40%

Phase Distribution

8

Early Stage

9

Mid Stage

16

Late Stage

Phase Distribution57 total trials
Early Phase 1First-in-human
1(1.8%)
Phase 1Safety & dosage
7(12.3%)
Phase 2Efficacy & side effects
9(15.8%)
Phase 3Large-scale testing
8(14.0%)
Phase 4Post-market surveillance
8(14.0%)
N/ANon-phased studies
24(42.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

74.5%

35 of 47 finished

Non-Completion Rate

25.5%

12 ended early

Currently Active

4

trials recruiting

Total Trials

60

all time

Status Distribution
Active(5)
Completed(35)
Terminated(12)
Other(8)

Detailed Status

Completed35
unknown8
Withdrawn6
Terminated6
Recruiting4
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
60
Active
4
Success Rate
85.4%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (1.8%)
Phase 17 (12.3%)
Phase 29 (15.8%)
Phase 38 (14.0%)
Phase 48 (14.0%)
N/A24 (42.1%)

Trials by Status

withdrawn610%
not_yet_recruiting12%
unknown813%
recruiting47%
terminated610%
completed3558%

Recent Activity

Clinical Trials (60)

Showing 20 of 60 trialsScroll for more
NCT07569861Not Applicable

Copeptin Measurement After Mannitol and Hypertonic Saline for the Diagnosis of Polyuria-polydipsia Syndrome

Not Yet Recruiting
NCT04921943Phase 4

Hypertonic Saline for MAC

Recruiting
NCT06069336Not Applicable

Nebulised 3% Hypertonic Saline Versus 0.9% Saline for Treating Patients Hospitalized With Acute Bronchiolitis

Completed
NCT04140214Phase 3

Randomised Open Label Trial of Hypertonic Saline and Carbocisteine in Bronchiectasis (CLEAR)

Completed
NCT03300648Phase 3

Treating Brain Swelling in Pediatric Cerebral Malaria

Completed
NCT00753987Phase 1

Tolerability of Hypertonic Saline in Infants With Cystic Fibrosis

Completed
NCT06470737Not Applicable

Investigation of Corticospinal Excitability Aspects of Itch and Pain

Completed
NCT06503523Not Applicable

The Effects of Performing a Motor Imagery Task on Cortical Excitability During Acute Experimental Muscle Pain and Acute Itch

Recruiting
NCT06443658Phase 3

Benefits of Inhalation of Hypertonic Saline Solution Prior to Physiotherapy ELTGOL Technique in Bronchiectasis

Recruiting
NCT00700050

Modulation by Sex Hormones of Inflammation and Susceptibility to Pseudomonas Aeruginosa in Cystic Fibrosis Airways

Completed
NCT04787198Not Applicable

Investigating Composite Biomarkers for Pain Catastrophizing

Recruiting
NCT06174584Early Phase 1

Comparison of Cow Milk and 15% Hypertonic Saline in the Treatment of Rectal Prolapse in Children

Completed
NCT04233606Not Applicable

Influence of Osmotic Stimulation of Vasopressin on Autonomic Function

Withdrawn
NCT06110429Phase 3

Sodium Lactate Versus Hypertonic Saline Solution in the Treatment of Intracranial Hypertensive Episodes in Severe Brain Injured Patients

Unknown
NCT04439994Not Applicable

Activation of miRNA and Proteins After Acute Experimental Pain. (miRNA: Micro RNA)

Completed
NCT02947126Phase 1

Multilevel Models of Therapeutic Response in the Lungs

Completed
NCT03750136Not Applicable

Furosemide Alone or Unexpectedly With Solution of Hypertonic Saline in Nephrotic Syndrome

Unknown
NCT02871778Phase 2

Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia

Completed
NCT02709109Phase 2

A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation

Completed
NCT02343445Phase 2

Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF)

Completed

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
60